Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

p>

Amicus will host a conference call to discuss financial and operational results for the second quarter 2009, today, August 5, 2009 at 5 p.m. EDT. Interested participants and investors may access the conference call by dialing 877-591-4949 (U.S./Canada) or 719-325-4889 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4035217.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com.

About NEA

New Enterprise Associates, Inc. (NEA) is a leading venture capital firm focused on helping entrepreneurs create and build major new enterprises that use technology to improve the way we live, work and play. Since its founding in 1978, the firm has followed the same core principles: supporting its entrepreneurs, providing an excellent return to its limited partners, and practicing its profession with the highest standards and respect. Through its affiliated funds, NEA focuses on investments at all stages of a company's development, from seed stage through IPO. With approximately $8.5 billion in committed capital, NEA's experienced management team has invested in over 650 companies, of which more than 16
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 BioConvergence team ... speaking faculty at 2013’s BioLogistics Summit in San ... coordinated by Cold Chain IQ and IQPC, addressed ... “complexity” is, in part, attributed to current trends ... “Implicit within these trends is an increase in ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... MN (PRWEB) June 19, 2013 Express ... abuse tests, today announced that it has received Class ... market and sell its DrugCheck® NxStep Onsite Drug ... use of the rapid screening device in near-patient settings, ... Drug Screen Cup received Health Canada Class III approval ...
(Date:6/18/2013)... 2013 Tabletop SEMs are inexpensive and ... have limited performance and capability such as small sample ... would normally provide better imaging performance and more analytical ... have a higher cost of maintenance. The Pemtron ... these two types of SEM product, offering competitive prices ...
Breaking Biology Technology:BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3
... U.S. Food and Drug Administration clears new implant for ... Innovations, Inc. (SBi),a single-source provider of products, technology and ... orthopedic industry, announced that its,Artelon(R) STT Spacer has been ... This product extends SBi,s line of surgically implanted, ...
... FRAZER, Pa., Sept. 21 Cephalon, Inc. (Nasdaq:,CEPH) ... Drug Application (NDA) to,the U.S. Food and Drug ... the treatment of patients with chronic,lymphocytic leukemia (CLL). ... disease with an estimated 15,000 new cases diagnosed ...
... CLARA, California, September 21, ChemAxon, a software solutions ... A ) today announced an,agreement to maintain the ... ChemAxon,s software suite. Agilent acquired,the Kalabie ELN from ... between Klee and ChemAxon to Agilent and ChemAxon. ...
Cached Biology Technology:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 2Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 3Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 4Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 5Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 2
(Date:6/19/2013)... specifically for human consumption qualifies as a gluten-free cereal ... (CD), scientists have confirmed in a study published in ... , Joyce Irene Boye and colleagues point out ... States alone have CD. They develop gastrointestinal and other ... that contain gluten-related proteins. Boye,s team sought to expand ...
(Date:6/19/2013)... NEW YORK , June 19, 2013  New ... #8,461,981 by the United States Patent and Trademark Office ... security systems that reflect whether guards have been injured, ... of an extensive portfolio under the Intellectual Properties Agreements ... Lisa Pamintuan , President of New ...
(Date:6/19/2013)... to contribute to a very large and potentially record-setting ... University of Michigan ecologist and colleagues who released their ... Bay. , The Gulf forecast, one of two announced ... an oxygen-depleted, or hypoxic, region of between 7,286 and ... 10 largest on record. , The low end of ...
Breaking Biology News(10 mins):New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4
... Earth Observatory of Singapore (EOS) which aspires to ... addressing several of civilisation,s most serious environmental threats ... change aims to provide invaluable research and ... could potentially save hundreds of thousands of lives. ...
... determining ways to speed the return of residents to ... The first step is providing better, more accessible ... architects and others says Dr. Dave Tilotta, associate professor ... first part of a multi-phase study examining the resilience ...
... Hopkins engineer is trying to coax human stem cells ... could someday be used to replace damaged tissue in ... Sharon Gerecht, an assistant professor of chemical and molecular ... received a $150,000 two-year grant from the March of ...
Cached Biology News:The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 2The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 3Defying the disaster: Researcher explores resilient housing 2Researcher seeks to turn stem cells into blood vessels 2Researcher seeks to turn stem cells into blood vessels 3
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Biology Products: